456 related articles for article (PubMed ID: 30310905)
21. (-)-Epigallocatechin-3-gallate inhibits human papillomavirus (HPV)-16 oncoprotein-induced angiogenesis in non-small cell lung cancer cells by targeting HIF-1α.
He L; Zhang E; Shi J; Li X; Zhou K; Zhang Q; Le AD; Tang X
Cancer Chemother Pharmacol; 2013 Mar; 71(3):713-25. PubMed ID: 23292117
[TBL] [Abstract][Full Text] [Related]
22. The combination of EGCG with warfarin reduces deep vein thrombosis in rabbits through modulating HIF-1α and VEGF via the PI3K/AKT and ERK1/2 signaling pathways.
Li Y; Ge JP; Ma K; Yin YY; He J; Gu JP
Chin J Nat Med; 2022 Sep; 20(9):679-690. PubMed ID: 36162953
[TBL] [Abstract][Full Text] [Related]
23. Epigallocatechin-3-gallate inhibits IGF-I-stimulated lung cancer angiogenesis through downregulation of HIF-1α and VEGF expression.
Li X; Feng Y; Liu J; Feng X; Zhou K; Tang X
J Nutrigenet Nutrigenomics; 2013; 6(3):169-78. PubMed ID: 24008975
[TBL] [Abstract][Full Text] [Related]
24. Oligomeric proanthocyanidins and epigallocatechin gallate aggravate autophagy of foam cells through the activation of Class III PI3K/Beclin1-complex mediated cholesterol efflux.
Jamuna S; Ashokkumar R; Sakeena Sadullah MS; Devaraj SN
Biofactors; 2019 Sep; 45(5):763-773. PubMed ID: 31237721
[TBL] [Abstract][Full Text] [Related]
25. Green tea extract and (-)-epigallocatechin-3-gallate inhibit hypoxia- and serum-induced HIF-1alpha protein accumulation and VEGF expression in human cervical carcinoma and hepatoma cells.
Zhang Q; Tang X; Lu Q; Zhang Z; Rao J; Le AD
Mol Cancer Ther; 2006 May; 5(5):1227-38. PubMed ID: 16731755
[TBL] [Abstract][Full Text] [Related]
26. PLGA-encapsulated tea polyphenols enhance the chemotherapeutic efficacy of cisplatin against human cancer cells and mice bearing Ehrlich ascites carcinoma.
Singh M; Bhatnagar P; Mishra S; Kumar P; Shukla Y; Gupta KC
Int J Nanomedicine; 2015; 10():6789-809. PubMed ID: 26586942
[TBL] [Abstract][Full Text] [Related]
27. Mechanisms of inhibition of tumor angiogenesis and vascular tumor growth by epigallocatechin-3-gallate.
Fassina G; Venè R; Morini M; Minghelli S; Benelli R; Noonan DM; Albini A
Clin Cancer Res; 2004 Jul; 10(14):4865-73. PubMed ID: 15269163
[TBL] [Abstract][Full Text] [Related]
28. DT-13 inhibited the proliferation of colorectal cancer via glycolytic metabolism and AMPK/mTOR signaling pathway.
Wei X; Mao T; Li S; He J; Hou X; Li H; Zhan M; Yang X; Li R; Xiao J; Yuan S; Sun L
Phytomedicine; 2019 Feb; 54():120-131. PubMed ID: 30668361
[TBL] [Abstract][Full Text] [Related]
29. Autophagy inhibition contributes to the synergistic interaction between EGCG and doxorubicin to kill the hepatoma Hep3B cells.
Chen L; Ye HL; Zhang G; Yao WM; Chen XZ; Zhang FC; Liang G
PLoS One; 2014; 9(1):e85771. PubMed ID: 24465696
[TBL] [Abstract][Full Text] [Related]
30. Green tea (-)-epigallocatechin gallate suppresses IGF-I and IGF-II stimulation of 3T3-L1 adipocyte glucose uptake via the glucose transporter 4, but not glucose transporter 1 pathway.
Ku HC; Tsuei YW; Kao CC; Weng JT; Shih LJ; Chang HH; Liu CW; Tsai SW; Kuo YC; Kao YH
Gen Comp Endocrinol; 2014 Apr; 199():46-55. PubMed ID: 24486085
[TBL] [Abstract][Full Text] [Related]
31. Targeting Glycolysis with Epigallocatechin-3-Gallate Enhances the Efficacy of Chemotherapeutics in Pancreatic Cancer Cells and Xenografts.
Wei R; Hackman RM; Wang Y; Mackenzie GG
Cancers (Basel); 2019 Oct; 11(10):. PubMed ID: 31590367
[TBL] [Abstract][Full Text] [Related]
32. [Epigallocatechin-3-gallate inhibits growth and angiogenesis of gastric cancer and its molecular mechanism].
Zhu BH; Zhan WH; He YL; Cai SR; Wang Z; Zhang CH
Zhonghua Wei Chang Wai Ke Za Zhi; 2009 Jan; 12(1):82-5. PubMed ID: 19145512
[TBL] [Abstract][Full Text] [Related]
33. (-)-Epigallocatechin-3-gallate inhibits growth of gastric cancer by reducing VEGF production and angiogenesis.
Zhu BH; Zhan WH; Li ZR; Wang Z; He YL; Peng JS; Cai SR; Ma JP; Zhang CH
World J Gastroenterol; 2007 Feb; 13(8):1162-9. PubMed ID: 17451194
[TBL] [Abstract][Full Text] [Related]
34. Epigallocatechin-3-Gallate Attenuates Adriamycin-Induced Focal Segmental Glomerulosclerosis via Suppression of Oxidant Stress and Apoptosis by Targeting Hypoxia-Inducible Factor-1α/ Angiopoietin-Like 4 Pathway.
Liu G; He L
Pharmacology; 2019; 103(5-6):303-314. PubMed ID: 30840953
[TBL] [Abstract][Full Text] [Related]
35. EGCG, a major component of green tea, inhibits tumour growth by inhibiting VEGF induction in human colon carcinoma cells.
Jung YD; Kim MS; Shin BA; Chay KO; Ahn BW; Liu W; Bucana CD; Gallick GE; Ellis LM
Br J Cancer; 2001 Mar; 84(6):844-50. PubMed ID: 11259102
[TBL] [Abstract][Full Text] [Related]
36. Epigallocatechin-3-gallate Enhances Radiation Sensitivity in Colorectal Cancer Cells Through Nrf2 Activation and Autophagy.
Enkhbat T; Nishi M; Yoshikawa K; Jun H; Tokunaga T; Takasu C; Kashihara H; Ishikawa D; Tominaga M; Shimada M
Anticancer Res; 2018 Nov; 38(11):6247-6252. PubMed ID: 30396944
[TBL] [Abstract][Full Text] [Related]
37. Epigallocatechin-3-Gallate Reduces Visceral Adiposity Partly through the Regulation of Beclin1-Dependent Autophagy in White Adipose Tissues.
Choi C; Song HD; Son Y; Cho YK; Ahn SY; Jung YS; Yoon YC; Kwon SW; Lee YH
Nutrients; 2020 Oct; 12(10):. PubMed ID: 33050029
[TBL] [Abstract][Full Text] [Related]
38. Novel D-ring analog of epigallocatechin-3-gallate inhibits tumor growth and VEGF expression in breast carcinoma cells.
Waleh NS; Chao WR; Bensari A; Zaveri NT
Anticancer Res; 2005; 25(1A):397-402. PubMed ID: 15816564
[TBL] [Abstract][Full Text] [Related]
39. (-)-Epigallocatechin gallate suppresses the growth of human hepatocellular carcinoma cells by inhibiting activation of the vascular endothelial growth factor-vascular endothelial growth factor receptor axis.
Shirakami Y; Shimizu M; Adachi S; Sakai H; Nakagawa T; Yasuda Y; Tsurumi H; Hara Y; Moriwaki H
Cancer Sci; 2009 Oct; 100(10):1957-62. PubMed ID: 19558547
[TBL] [Abstract][Full Text] [Related]
40. (-)-Epigallocatechin gallate sensitizes breast cancer cells to paclitaxel in a murine model of breast carcinoma.
Luo T; Wang J; Yin Y; Hua H; Jing J; Sun X; Li M; Zhang Y; Jiang Y
Breast Cancer Res; 2010; 12(1):R8. PubMed ID: 20078855
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
